Impact of chronic kidney disease on the risk of clinical outcomes in patients with cancer-associated venous thromboembolism during anticoagulant treatment

Journal of Thrombosis and Haemostasis

Volumn 11, Issue 11, 2013, Pages 1968-1976

  Kooiman, J ^a   den Exter, P L ^a   Cannegieter, S C ^a   le Cessie, S ^a   del Toro, J ^b   Sahuquillo, J C ^c   Pedrajas, J M ^d   Huisman, M V ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^c Hospital Municipal de Badalona   (Spain)

^d HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

Chronic; Coumarins; Heparin; Low molecular weight; Neoplasm; Renal insufficiency; Venous thrombosis

Indexed keywords

ANTIVITAMIN K; LOW MOLECULAR WEIGHT HEPARIN; ANTICOAGULANT AGENT; VITAMIN K GROUP;

ADULT; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CANCER PATIENT; CHRONIC KIDNEY DISEASE; DISEASE ASSOCIATION; FATALITY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEOPLASM; PRIORITY JOURNAL; RECURRENT DISEASE; RISK ASSESSMENT; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM; AGED; ANTAGONISTS AND INHIBITORS; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; COHORT ANALYSIS; COMPLICATION; FOLLOW UP; MIDDLE AGED; MULTICENTER STUDY; REGISTER; RISK; TIME;

AGED; ANTICOAGULANTS; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HEMORRHAGE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; NEOPLASMS; RECURRENCE; REGISTRIES; RISK; TIME FACTORS; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM; VITAMIN K;

EID: 84887545937     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.12411     Document Type: Article

References (25)

1. Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 2005; 293: 715-22.
2. Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ III. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med 2000; 160: 809-15.
3. De Lorenzo F, Dotsenko O, Scully MF, Tymoshchuk M. The role of anticoagulation in cancer patients: facts and figures. Anticancer Agents Med Chem 2006; 6: 579-87.
4. Carrier M, Lee AY. Prophylactic and therapeutic anticoagulation for thrombosis: major issues in oncology. Nat Clin Pract Oncol 2009; 6: 74-84.
5. Bergqvist D, Caprini JA, Dotsenko O, Kakkar AK, Mishra RG, Wakefield TW. Venous thromboembolism and cancer. Curr Probl Surg 2007; 44: 157-216.
6. Lee AY. Treatment of venous thromboembolism in cancer patients. Best Pract Res Clin Haematol 2009; 22: 93-101.
7. Trujillo-Santos J, Ruiz-Gamietea A, Luque JM, Samperiz AL, Garcia-Bragado F, Todoli JA, Monreal M. Predicting recurrences or major bleeding in women with cancer and venous thromboembolism. Findings from the RIETE Registry. Thromb Res 2009; 123(Suppl. 2): S10-5.
8. Hutten BA, Prins MH, Gent M, Ginsberg J, Tijssen JG, Buller HR. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol 2000; 18: 3078-83.
9. Prandoni P, Lensing AW, Piccioli A, Bernardi E, Simioni P, Girolami B, Marchiori A, Sabbion P, Prins MH, Noventa F, Girolami A. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002; 100: 3484-8.
10. Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, Rickles FR, Julian JA, Haley S, Kovacs MJ, Gent M. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349: 146-53.
11. Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ, Nelson ME, Wells PS, Gould MK, Dentali F, Crowther M, Kahn SR. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141: e419S-94S.
12. Janus N, Launay-Vacher V, Byloos E, Machiels JP, Duck L, Kerger J, Wynendaele W, Canon JL, Lybaert W, Nortier J, Deray G, Wildiers H. Cancer and renal insufficiency results of the BIRMA study. Br J Cancer 2010; 103: 1815-21.
13. Monreal M, Falga C, Valle R, Barba R, Bosco J, Beato JL, Maestre A. Venous thromboembolism in patients with renal insufficiency: findings from the RIETE Registry. Am J Med 2006; 119: 1073-9.
14. van Schouwenburg IM, Mahmoodi BK, Veeger NJ, Kluin-Nelemans HC, Gansevoort RT, Meijer K. Elevated albuminuria associated with increased risk of recurrent venous thromboembolism: results of a population-based cohort study. Br J Haematol 2012; 156: 667-71.
15. den Exter PL, Hooijer J, Dekkers OM, Huisman MV. Risk of recurrent venous thromboembolism and mortality in patients with cancer incidentally diagnosed with pulmonary embolism: a comparison with symptomatic patients. J Clin Oncol 2011; 29: 2405-9.
16. Barraclough LH, Field C, Wieringa G, Swindell R, Livsey JE, Davidson SE. Estimation of renal function - what is appropriate in cancer patients? Clin Oncol (R Coll Radiol) 2008; 20: 721-6.
17. Holweger K, Lipp HP, Dietz K, Hartmann JT, Bokemeyer C. Novel algorithm for more accurate calculation of renal function in adults with cancer. Ann Pharmacother 2008; 42: 1749-57.
18. Kleber M, Cybulla M, Bauchmuller K, Ihorst G, Koch B, Engelhardt M. Monitoring of renal function in cancer patients: an ongoing challenge for clinical practice. Ann Oncol 2007; 18: 950-8.
19. Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005; 3: 692-4.
20. Zondag W, Mos IC, Creemers-Schild D, Hoogerbrugge AD, Dekkers OM, Dolsma J, Eijsvogel M, Faber LM, Hofstee HM, Hovens MM, Jonkers GJ, van Kralingen KW, Kruip MJ, Vlasveld T, de Vreede MJ, Huisman MV. Outpatient treatment in patients with acute pulmonary embolism: the Hestia Study. J Thromb Haemost 2011; 9: 1500-7.
21. den Exter PL, Hooijer J, Dekkers OM, Huisman MV. Vitamin K antagonists versus LMWH in the treatment of venous thromboembolism in patients with malignancy; an observational survey in daily practice. Thromb Res 2012; 129: S183. Ref Type: Abstract
22. Louzada ML, Carrier M, Lazo-Langner A, Dao V, Kovacs MJ, Ramsay TO, Rodger MA, Zhang J, Lee AY, Meyer G, Wells PS. Development of a clinical prediction rule for risk stratification of recurrent venous thromboembolism in patients with cancer-associated venous thromboembolism. Circulation 2012; 126: 448-54.
23. Frydman A. Low-molecular-weight heparins: an overview of their pharmacodynamics, pharmacokinetics and metabolism in humans. Haemostasis 1996; 26(Suppl. 2): 24-38.
24. Schmid P, Brodmann D, Odermatt Y, Fischer AG, Wuillemin WA. Study of bioaccumulation of dalteparin at a therapeutic dose in patients with renal insufficiency. J Thromb Haemost 2009; 7: 1629-32.
25. Lim W, Dentali F, Eikelboom JW, Crowther MA. Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med 2006; 144: 673-84.